Compare FEED & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FEED | GLMD |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.2M |
| IPO Year | 2014 | 2013 |
| Metric | FEED | GLMD |
|---|---|---|
| Price | $0.40 | $4.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 292.4K | 108.1K |
| Earning Date | 04-15-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.41 |
| 52 Week High | $6.09 | $5.45 |
| Indicator | FEED | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
ENvue Medical Inc is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. It focuses on two technology platforms: the ENvue Navigation Platform, which provides an electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract; FDA 510(k) cleared for adult use, it provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Its Medical advances non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation in healthcare environments, and the company's acoustic-based therapeutic technologies.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.